The role of bortezomib in the treatment of lymphoma.
作者： Paul Barr , Richard Fisher , Jonathan Friedberg
DOI: 10.1080/07357900701579570
关键词:
摘要: Bortezomib is the first of proteasome inhibitors to be used clinically. Among various cancers susceptible inhibition are non-Hodgkin's lymphomas. Mantle cell lymphoma appears particularly sensitive, leading FDA approval bortezomib in patients who have received at least one prior therapy. This demonstration clinical efficacy has led an explosion research attempting further understand anti-tumor effect and investigations exploring combination with other agents. In this review, we will detail results ongoing trials utilizing Hodgkin's lymphoma.
informahealthcare.com参考文章(83)
Hélène Merle-Béral, Karim Maloum, Satoshi Ömura, Henri Magdelénat, Jozo Delic, Peggy Masdehors, Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood. ,vol. 96, pp. 269- 274 ,(2000) , 10.1182/BLOOD.V96.1.269
Hongyu Ni, Melek Ergin, Qin Huang, Jian-Zhong Qin, Hesham M. Amin, Robert L. Martinez, Shahnaz Saeed, Kevin Barton, Serhan Alkan, Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: downregulation of NF-κB induces apoptosis British Journal of Haematology. ,vol. 115, pp. 279- 286 ,(2001) , 10.1046/J.1365-2141.2001.03102.X
Leslie Popplewell, Kenneth Offit, Suresh C. Jhanwar, R.S.K. Chaganti, Pulivarthi H. Rao, Jane Houldsworth, Katerina Dyomina, Nasser Z. Parsa, Juan C. Cigudosa, Diane C. Louie, Chromosomal and gene amplification in diffuse large B-cell lymphoma Blood. ,vol. 92, pp. 234- 240 ,(1998) , 10.1182/BLOOD.V92.1.234.413K22_234_240
Gaël Roué, Patricia Pérez-Galán, Mónica López-Guerra, Neus Villamor, Elias Campo, Dolors Colomer, Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level Journal of Immunology. ,vol. 178, pp. 1923- 1930 ,(2007) , 10.4049/JIMMUNOL.178.3.1923
Carol Aghajanian, Sandra Pezzulli, Martee L. Hensley, Christine S. Pien, Don S. Dizon, Paul Sabbatini, Vincent Miller, Christina Canales, Adil Daud, Peter J. Elliott, Steven Soignet, Julian Adams, David R. Spriggs, A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clinical Cancer Research. ,vol. 8, pp. 2505- 2511 ,(2002)
Gerassimos A. Pangalis, Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Maria Christina Kyrtsonis, Efstathios Castritis, Athanasios Bitsaktsis, Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib. Haematologica. ,vol. 90, pp. 1655- 1658 ,(2005) , 10.3324/%X
K Warzocha, G Salles, J Bienvenu, Y Bastion, C Dumontet, N Renard, E M Neidhardt-Berard, B Coiffier, Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. Journal of Clinical Oncology. ,vol. 15, pp. 499- 508 ,(1997) , 10.1200/JCO.1997.15.2.499
Eric S Lightcap, Teresa A McCormack, Christine S Pien, Vincent Chau, Julian Adams, Peter J Elliott, Proteasome Inhibition Measurements: Clinical Application Clinical Chemistry. ,vol. 46, pp. 673- 683 ,(2000) , 10.1093/CLINCHEM/46.5.673
GM Cohen, JB Almond, The proteasome: a novel target for cancer chemotherapy. Leukemia. ,vol. 16, pp. 433- 443 ,(2002) , 10.1038/SJ.LEU.2402417
Caroline A Heckman, John W Mehew, Linda M Boxer, NF-κB activates Bcl-2 expression in t (14 ; 18) lymphoma cells Oncogene. ,vol. 21, pp. 3898- 3908 ,(2002) , 10.1038/SJ.ONC.1205483